ABSTRACT. In many countries vitamin K prophylaxis at birth is recommended to prevent bleeding in infants due to vitamin K deficiency. Because the incidence of clinical vitamin K deficiency is very low, such a vitamin K administration should be completely safe. However, an increase in sister chromatid exchanges in lymphocytes of fetal sheep 24 h after injection of vitamin K, has been reported. Therefore, a study concerning genotoxicity of vitamin K, in man was conducted. Sister chromatid exchanges and chromosome aberrations were analyzed in peripheral blood lymphocytes of six newborns 24 h after intramuscular administration of 1 mg vitamin K, and in six control neonates. The mean number of sister chromatid exchanges per metaphase in the vitamin K group was 8.88 f 1.22 as compared with 9.05 f 1.14 in the control group ( 
The problem of bleeding in infants due to vitamin K deficiency has been recognized worldwide. In many countries vitamin K interchanges of DNA at apparently homologous chromosomal sites after replication. These exchanges presumably involve DNA breakage and reunion. Although there is no perfect agreement between the ability of a compound to produce SCE and its mutagenicity or carcinogenicity, there is a high degree of correlation (3). Israels et al. (2) postulated that the relative vitamin Kdeficient state of the newborn may in fact play a role in the protection of the fetus in utero by reducing the risk of mutagenic events during this period of rapid cell proliferation. The question arises whether the results of the study of Israels et al. indicate a genotoxic or carcinogenic risk to man, specifically when the vitamin is administered during early life. Moreover, Golding et al. (4) reported a statistical association between childhood cancer and vitamin K administration (among other drugs in the 1st wk of life). This association was found unexpectedly and fitted no prior hypothesis. The need for further research was stressed by the authors. To our knowledge, cytogenetic studies concerning genotoxicity of vitamin K, in man have as yet not been performed.
Apart from SCE assays, another way of testing for cytogenetic mutagenicity is to analyze CA. CA reflect damage of the chromosome-or chromatid-type and can be observed as breaks, acentric fragments, minutes, ring chromosomes, and gaps. Gaps are defined as regions in the chromatid structure that are achromatic, thus, the chromosome structure is not really discontinued (5) . Because CA and SCE are two different cytogenetic end points of mutagenic action, they are complementary (6) . Neither CA nor SCE have been studied before in human neonates exposed to vitamin K,.
The aim of this case-controlled clinical trial is to determine whether the administration of 1 mg vitamin K, intramuscularly after birth influences the occurrence of SCE and CA in cultured peripheral blood lymphocytes.
MATERIALS AND METHODS
prophylaxis at birth is recommended to prevent this hazard. Introduction of such a prophylaxis appeared to have spectacular results on the incidence of this so-called Haemorrhagic Disease of the Newborn (I). Because the incidence of clinical vitamin K deficiency is very low, this vitamin K supplementation should be completely safe. However, in 1987, Israels et al. (2) reported a dose-dependent increase of the frequency of SCE in lymphocytes after in vitro exposure to vitamin K I . In vivo exposure, tested in five fetal sheep given 1 mg of vitamin K1 i.v., also resulted in an increase in SCE 24 h after injection. SCE represent The study was approved by the local medical ethical committee. Informed consent was obtained from the parents. Twelve healthy breast-fed newborns, delivered in our hospital, were recruited for this study. Selection criteria were delivery at term (37-42 wk), birth weight over 2500 g, and Apgar score at 5 min of seven or more. The mother could not be on a special diet, smoke, abuse alcohol, or take any medication during the last month of pregnancy, except for iron or folic acid. Arterial cord blood pH, mode of delivery, and medication of the mother during labor were recorded. All infants had an arterial cord blood pH over 7.24, except for subject 7, who had a pH of 7.17. All children were delivered vaginally, except for subject 1, who was born by cesarean section. In two cases oxytocin was given to the mother during labor (subjects 3 and 1 1). The infants were randomly divided into two groups; six received 1 mg vitamin K I (Konakion; Hoffman-La Roche, Basel, Switzerland) intramuscularly, the other six received no medication. Some characteristics of the neonates are given in Table l . No item differed significantly between the groups. After 24 h, 5 mL of blood were drawn by aseptic venipuncture: 2 mL of heparinized blood and approximately 3 mL of blood with no additive. The latter was kept in the dark immediately after sampling, centrifugated (3000 x g for 5 min), and stored at -20°C until vitamin K I determination. All samples were coded to provide blind cytogenetic analysis.
Vitamin KI. Vitamin K I was measured in 1 -mL serum samples by a two-step HPLC procedure, according to the method of Lambert et al. (7, 8) . A few modifications were applied. The assays were performed with two Spectra Physics SP8800 systems (Spectra Physics, Santa Clara, CA) equipped with Rheodyne 7 125 manual injectors (Rheodyne, Cotati, CA), with 100-pL sample loops. Vitamin was used as an internal standard. The first HPLC step was used for preseparation of vitamin K I and KI(25) on a microspher-Si column (Chrompack, Middelburg, The Netherlands). The locations of vitamin K, and internal standard were detected with a variable wavelength detector model 770 (Spectra Physics) set at 248 nm. Final separation and quantitation were performed during the second HPLC step, using a microspher-C18 column (Chrompack) for separation and postcolumn chemical reduction with tetramethylammoniumoctahydridotriborate for fluorescence detection (A,, = 325 nm, A, , = 450 nm) with a Waters 470 fluorescence detector (Waters Associates, Millipore Corp., Milford, MA). Concentrations were calculated from relative peak heights of vitamin K I versus known amounts of internal standard. The lower limit of detection was 0.045 ng/mL; however, the detection limit was dependent on the recovery of internal standard and the amount of serum extracted.
Cytogenetics. Peripheral lymphocyte cultures were initiated within 2 h after blood collection. For each culture two containers with medium (8 mL RPMI 1640 medium, supplemented with 15% FCS, heparin, phytohemagglutinin, penicillin, and streptomycin) were each supplied with 0.2 mL neonatal whole blood. From all infants two cultures were set up: one with and the other without BrdU (final concentration 10 pg/mL). BrdU was present in the medium during the whole culture period. All cultures were grown in the dark at 37°C for exactly 72 h. Colcemid (final concentration 0.2 pg/mL) was added 90 min before harvesting. Chromosome spreads were made according to routine procedures. The standard cultures without BrdU were applied for aberration screening by one technician. From every child 100 mitoses were studied after conventional Giemsa staining and all CA were recorded and photographed. The cultures with BrdU were used for SCE studies. From every infant 25 complete mitoses were photographed in fluorescence microscopy after the chromosomes had been stained with acridine orange (9) . In this way the number of SCE could easily be counted from the photograph.
For statistical evaluation the unpaired t test was applied for study-population characteristics, SCE, and CA results. Vitamin K1 concentrations were compared by Wilcoxon's two-sample test. All values are given as means k SD. 
RESULTS
The vitamin K I concentrations and the number of SCE and CA of each subject are presented in Table 2 . SCE results are missing for subjects 4 and 8 because of bad growth of BrdU cultures. Less than 20 mitoses were suitable for SCE analysis. Conventional growth was adequate and chromosome aberrations were counted. During determination of vitamin K I in subject 4, a technical error was encountered. Because of the small volumes of serum available from the neonates, the procedure could not be repeated.
Twenty-four h after injection of 1 mg vitamin KI, plasma levels ranged from 1 14.6 to 1 150.5 ng/mL (255 to 2555 x M). Vitamin K1 concentrations in the supplemented group were raised some 5000-fold as compared with the control group ( p = 0.006). In two subjects of the control group, the vitamin K I concentration was not even detectable. Because of differences in volume of serum available, the detection limit ranged from 0.045 to 0.198 ng/mL in these samples.
In the vitamin K-supplemented group, the mean number of SCE was 8.88 + 1.22 per metaphase compared with 9.05 t 1.14 in the control group. The groups did not differ significantly ( p = 0.82'1. . .-, -When the total number of chromosome and chromatid breaks as well as gaps was taken into account, a mean number of 3.00 + 2.6 1 CA per 100 mitoses was detected in the vitamin K group. In the control group a mean number of 2.50 + 1.87 per 100 mitoses was found (NS, p = 0.71). When gaps were excluded, the mean numbers amounted to 1.50 + 1.05 and 2.50 + 1.87, respectively. Still, no significant difference was present ( p = 0.28).
DISCUSSION
As would be expected, 24 h after the intramuscular administration of 1 mg vitamin K I serum concentrations vitamin K l were extremely high, the mean being 536 ng/mL. This finding is in accordance with the mean levels of 444 ng/mL reported by McNinch et al. (10) and of 348 ng/mL by Lucock el al. (1 I). McNinch et al. (10) detected a peak level of 1781 ng/mL after 12 h. This shows that the blood lymphocytes in the vitamin K group certainly have been exposed to extremely high levels of vitamin K before sampling. Previous studies have shown that the plasma level declines rapidly ( 12) .
Several short-term mutagenicity test systems have been developed to identify agents that can adversely affect the genetic material of cells (The American Industrial Health Council, 13). This property may indicate the potential for a number of adverse effects, one of which is carcinogenicity. There is a clear and justifiable rationale for the use of genetic toxicology assays, but they are less than perfect. Accuracy, which is a combination of sensitivity and specificity, is about 60%. Therefore, one assay will be insufficient (13, 14) . The Ames/Salmonella typhimurium assay is the test most commonly used for evaluation of chemicals in vitro (15) . Vitamin K , was not mutagenic in this test (16) . A negative Ames test, however, does not exclude carcinogenicity, inasmuch as a negative predictive value of only 5 1 % was calculated (14) . In other words, performance of an Ames test alone is inadequate to determine whether vitamin KI is genotoxic. Moreover, Israels et al. (2) did report an increase of SCE in lymphocytes after in vitro and in vivo exposure to vitamin K I . In vitro exposure was analyzed in cultured lymphocytes of human placental blood and adult female blood with added vitamin K l at a concentration of 1 x 10-% (450 ng/mL). Consequently, the lymphocytes that were stimulated to replicate by phytohemagglutinin were exposed for at least 48 h to a high concentration of vitamin K I . This is quite different from in vivo situations, where high concentrations of vitamin K I are only temporary and lymphocytes normally do not divide. In vivo exposure was tested in fetal sheep in utero given 1 mg of vitamin K, i.v. SCE were 552 CORNELISSEN ET AL. 
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Because the aim of the present investigation was to determine whether there are indications that vitamin K may have genotoxic effects in the human neonate, we opted for an in vivo study in humans with the intention to reflect the clinical situation, especially because several unknown factors may hamper generalization of in vitro and animal studies to clinical practice. SCE and CA analyses were performed on cultured lymphocytes after exposure of the neonate in vivo. Accordingly, the vitamin will be subjected to the spectrum of activating and deactivating enzymes as far as these are developed in the newborn (17) . Detoxification or formation of toxic degradation products might be different in fetal lambs as compared with human neonates. In fetal mice SCE response was found to decline with gestational age (1 8) . Administration of mitomycin C, a mutagen that does not require metabolic activation, and of cyclophosphamid, a drug activated by the liver into a potent alkylating agent, both resulted in a decline in SCE with gestational age. Repair capacities may vary with gestational age.
Fortunately, no carcinogenic metabolites are reported for vitamin K I . In the liver vitamin K is first reduced to vitamin K hydroquinone and subsequently oxidized to vitamin K-2,3-epoxide. This oxidation is connected with the carboxylation reaction in which glutamic acid residues of vitamin K-dependent coagulation factors are carboxvlated. Subseauentlv. vitamin K-2.3-epoxide is converted back into natural ;itam& K and the cycle is complete. In adults vitamin K I is excreted in urine and bile as more polar metabolites (carboxylic acids) conjugated with glucuronic acid. An enterohepatic circulation is present (19) . After supplementation with vitamin K I , urinary and fecal excretion is virtually complete after 3 d and amounts to about 60% of the dose (19) . Whether fetal vitamin K metabolism differs from adult metabolism is unknown but conceivable.
Besides advantages, in vivo testing carries the problem that unknown confounding factors may disturb the conclusions. Age, sex, tobacco smoking, medication, and alcohol abuse may be confounders (20) . In the present study these items were excluded or otherwise randomized. We were unable to detect an increase in SCE 24 h after the administration of 1 mg vitamin K I intramuscularly.
Because additional negative results were achieved in the CA analysis, which is a less sensitive but more specific short-term mutagenicity test (14) , a genotoxic effect is improbable.
When the effects of supplementation with vitamin K are considered, not only plasma concentrations (and lymphocyte exposure) have to be taken into account. Concentrations in other tissues may differ. It might be possible that because of accumulation hepatic concentrations higher than plasma concentrations are reached. The hepatic vitamin K I level in unsupplemented term neonates is reported to be about 1 ng/g liver (fresh weight) with a wide range (21) . This is 10-fold higher than the plasma level of about 0.1 ng/mL in our control group. Shearer et al. (21) have reported hepatic vitamin K I concentrations 10 h after intramuscular administration of 0.5 to 1.0 mg vitamin K, of approximately 200 ng/g and after 1 to 4 d, 500-2000 ng/g. These levels are comparable to the plasma levels in our supplemented group, so there are no indications that higher concentrations are reached in the liver than in the blood after a single intramuscular dose of vitamin KI.
In conclusion, as yet there is no evidence for cytogenetic toxicity due to the administration of 1 mg vitamin K I intramuscularly to the newborn infant.
